Companies like Turing Pharmaceuticals and KV Pharmaceuticals have grabbed headlines recently for their aggressive pricing strategies. Whether these strategies are justified or even successful is not the point. Rather, what is important is the negative public perception that significant price hikes create for the industry as a whole.
In this climate, the industry needs to do a better job of talking about how prices are set and how that money is invested—otherwise we risk losing control of how we price our products and operate our businesses.
Fill the form below to download the full White Paper:
EVERSANA employs a team of over 2500 professionals across 27 locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…